Evidence map›Paper›PMID 38329493›Full record

SynthesisInternational urogynecology journal2024

Use of Methenamine for Urinary Tract Infection Prophylaxis: Systematic Review of Recent Evidence.

Spencer M Davidson, Jamie N Brown, Clayton B Nance, Mary L Townsend

Registry-linked trialAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in International urogynecology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06953271 (Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06953271 phase4recruitingnot on this mapstarted 2025, after this paper: background citation

Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial

TypeinterventionalSponsorWomen and Infants Hospital of Rhode IslandRan2025 to 2027Enrolled164ConditionsOveractive Bladder (OAB), Urinary Tract Infection (Diagnosis)ArmsMethenamine Hippurate, Typically prescribed oral antibiotic prophylaxis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. The MAK collection for occupational health and safety · 2026
    Review
  2. Article
  3. Urinary tract infections in immunocompromised patients.Current opinion in infectious diseases · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Spencer M DavidsonGeriatric Research Education and Clinical Center, Durham VA Health Care System, Durham, NC, USA.ORCID 0000-0002-7409-7496
Jamie N BrownPharmacy Service, Durham VA Health Care System, 508 Fulton St. (119), Durham, NC, 27705, USA. Jamie.Brown2@va.gov.ORCID 0000-0002-6839-5948
Clayton B NancePharmacy Service, Durham VA Health Care System, 508 Fulton St. (119), Durham, NC, 27705, USA.
Mary L TownsendPharmacy Service, Durham VA Health Care System, 508 Fulton St. (119), Durham, NC, 27705, USA.ORCID 0000-0002-9954-4846
Campbell University · USDuke University · USDurham VA Health Care System · USGeriatric Research Education and Clinical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisAntibiotic resistance is an unavoidable consequence of antibiotic use and growing rates of resistance are an urgent issue. Methenamine is a non-antibiotic alternative used for urinary tract infection (UTI) prophylaxis. The objective of this review is to evaluate recently published literature regarding the efficacy and safety of methenamine for UTI prophylaxis.

methodsPubMed, Embase, and CENTRAL databases were queried in March 2023 using the following search terms: urinary tract infection, cystitis, bacteriuria, or dysuria, and methenamine. Studies prior to 2012 were excluded from this review to focus on appraisal of the most recent evidence. Prospective and controlled retrospective trials were included for review.

resultsA total of seven studies (three prospective and four retrospective) met the inclusion criteria for review. Two of the 3 prospective studies demonstrated no or non-inferior differences in clinical efficacy to prevent recurrent UTIs between methenamine and antibiotic prophylaxis and the third showed decreased rates of UTI with methenamine use in patients with short-term indwelling catheters compared with cranberry alone. The retrospective studies consistently supported the efficacy and safety of methenamine for UTI prophylaxis in a variety of populations and clinical settings. Adverse effects reported with methenamine were similar to comparators and included nausea, abdominal pain, and headache.

conclusionsThe use of methenamine for UTI prophylaxis was shown to be effective in a variety of settings without an increased risk of adverse effects compared with prophylactic antibiotics. Larger blinded clinical trials are needed to further define the role of methenamine in UTI prophylaxis.

Indexed as

MethenamineUrinary Tract InfectionsAntibiotic ProphylaxisFemaleHumansMethenamineAntibiotic resistanceAntibiotic-sparing agentAntimicrobial stewardshipProphylactic antibioticRecurrent urinary tract infectionWomen’s health

Identifiers

PMID38329493
OpenAlexW4391653327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.